| Report Code: A01537 | Pages: 237 | Nov 2020 | 31251 Views | ||
| Author(s) : Ravi T, Apoorva S , Onkar S | Tables: 74 | Charts: 72 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Hiv Drugs Market
Request Now !The HIV drugs market size was valued at $30,891.48 million in 2019, and is expected to reach $36,495.47 million by 2027, registering a CAGR of 3.8% from 2020 to 2027. Human immunodeficiency virus (HIV) is a chronic and life-threatening disease, which can be transferred from one person to another through blood-to-blood and sexual contact. It is a virus, which attacks immune cells known as CD-4 cells, making the body susceptible to infections and other diseases. Over the years, the rise in prevalence of HIV disease worldwide has positively influenced the demand for HIV drugs. HIV drugs help to prevent the multiplication of HIV virus, thereby reducing the risk of its transmission.
COVID-19 lockdowns and other restrictions disrupted HIV testing and in many countries led to steep drops in diagnoses and referrals to HIV treatment worldwide. The pandemic has impacted the growth of HIV drugs market by suspending and resuming drug supplies. Additionally, declines in new prescriptions for patients in the US, Europe and other regions/countries affected by COVID have dampened global demand for antiretroviral and antibiotic products. In addition, failure of suppliers to deliver ARVs (antiretroviral drug) on time, shutdown of land & air transport services, and limited access to health services within countries as a result of the pandemic are anticipated to negatively impact the HIV drugs market in the future.
Limited supply of ARVs (antiretroviral drug) from manufacturers and disruption of land & air transport services is expected to negatively impact the HIV drugs market.
Furthermore, rescheduling of HIV treatment procedures may result in a backlog of patients in the future. Medication and lifestyle changes can be recommended for these cases until further notice. Moreover, in countries, such as the U.S., there are private hospitals and clinics that treat HIV. However, clinics and patients are suggested to maintain social distancing norms. Therefore, all these factors are anticipated to impact the HIV drugs market as well in the future.
The major factors that boost the HIV drug market growth include increase in prevalence of HIV and rise in treatment & diagnosis rate. Moreover, there is an escalation in government initiatives to increase awareness among people about HIV cause, symptoms, available treatment options, and the crucial role of these treatments to control the HIV virus growth. Therefore, rise in awareness through such government initiatives is also expected to drive the HIV drugs market growth. However, stringent government regulations for the approval and commercialization of HIV drugs are expected to restrain the market growth.
The factors responsible for the growing prevalence rate include unprotected sex, contaminated needles or syringes, and majorly the lack of awareness about the mode of transmission. A vital factor driving the HIV-1 market growth is the concerted efforts of the government and various NGOs to provide at-risk individuals with greater accessibility to disease testing and treatment for infected persons. Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, acts as another factor that contributes to the demand for HIV drugs.
The global HIV drugs market is bifurcated into medication class and region. On the basis of medication class, the market is classified into multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FI), entry inhibitors, and HIV integrase strand transfer inhibitors. Based on region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, the UK, France, Spain, Italy, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
On the basis of medication class, the multi-class combination drugs segment holds the largest market share as it involves the most advanced technique used for the treatment of HIV infection. Furthermore, this is attributed to the increase in adoption of drugs from this medication class owing to their better results in the control of HIV & related co-infections and their ease in consumption & adherence.
Asia-Pacific presents lucrative opportunities for key players operating in the HIV drugs market, owing to increase in population coupled with high growing geriatric population. In addition, rise in healthcare expenditure and developing guidelines are expected to propel the market growth in the region.
The report provides a comprehensive analysis of key players that operate in the HIV drugs market, such as Boehringer Ingelheim International GmbH, Merck & Co., Inc., Pfizer Inc., Gilead Sciences, Inc., GalaxoSmithKline plc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., AbbVie, and Cipla.
Key Benefits for Stakeholders
Key market segments
By Medication Class
Multi-class Combination Drugs
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Protease Inhibitors(PIs)
Entry Inhibitors
HIV Integrase Strand Transfer Inhibitors
By Region
Key Players of HIV Drugs Market
Loading Table Of Content...
The adoption of HIV drugs is expected to witness significant rise with increase in prevalence of HIV infection, growth in treatment & diagnosis rate with rise in awareness, and FDA approvals for novel products and their wide acceptance among patients. Increase in government initiatives to control HIV further fuels the market growth. The Asia-Pacific and LAMEA regions are expected to offer lucrative growth opportunities to the key players in the industry.
The North America and Europe markets hold larger share in the HIV drugs market due to the rising cases of HIV-infected people and the presence of top pharmaceutical companies in these regions. Moreover, the well-established healthcare systems in these regions leading to higher diagnosis & treatment rate is one of the major reasons for the higher share of North America and Europe in the global HIV drugs market.
A. The total market value of HIV drugs market is $30,891.48 million in 2019.
A. The forcast period for HIV drugs market is 2020 to 2027
A. The market value of HIV drugs market in 2027 is $ 36,495.47 million.
A. The base year is 2019 in HIV drugs market
A. Top companies such as GlaxoSmithKline plc., Cipla Limited, F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.
A. In medication class type, multi-class combination drugs segment is the most influencing segment. Hence, This is due to the increase in adoption of drugs from this medication class owing to their better results in the control of HIV & related coinfections and their ease in consumption & adherence.
A. The major factor that fuels the growth of the global HIV drugs market includesincrease in prevalence of HIV globally, and rising treatment & diagnosis rate. In addition, there is increase in government initiatives to increase awareness among people about HIV cause, symptoms, available treatment options, and the crucial role of these treatments in the control of HIV virus growth. Thus, raising awareness through such government initiatives are also expected to drive the HIV drugs market. However, stringent government regulations for the approval and commercialization of HIV drugs and side effects of HIV restrain the growth of the market.
A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the emerging countries. This is due to improvement in health awareness, development in healthcare infrastructure, and rise in number of hospitals & ambulatory surgical centers equipped with advanced medical facilities.
A. HIV (human immunodeficiency virus) is a virus that attacks the body's immune system. The virus can be transmitted through contact with infected blood, semen or vaginal fluids. If HIV is not treated, it can lead to AIDS (acquired immunodeficiency syndrome).
A. No cure exists for HIV/AIDS, but strict adherence to antiretroviral regimens (ARVs) can dramatically slow the disease's progress as well as prevent secondary infections and complications.
Start reading instantly.
This Report and over 19,257+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
